Bioprocessing Quality Control Outlook: Analytical Methods for Biologics Confirmation & Contaminant
公開 2026/04/02 16:51
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Biologics Identity Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Biologics Identity Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical quality assurance directors, regulatory affairs professionals, and contract testing organizations, confirming the identity and authenticity of biologic products—monoclonal antibodies, vaccines, cell/gene therapies, and recombinant proteins—is a critical regulatory requirement before product release. The global Biologics Identity Testing market addresses this need through analytical methods and assays that verify product identity, expected molecular structure, sequence, biological activity, and distinguish from impurities or contaminants. As the biologics pipeline expands and regulatory scrutiny intensifies, demand for specialized identity testing services continues to grow.
The global market for Biologics Identity Testing was estimated to be worth US$ 7391 million in 2025 and is projected to reach US$ 12750 million, growing at a CAGR of 8.2% from 2026 to 2032. This steady growth reflects increasing biologic drug approvals, biosimilar development, and outsourcing of testing to specialized CROs.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096823/biologics-identity-testing
Analytical Confirmation for Biologic Product Authenticity
Biologics Identity Testing refers to the set of analytical methods and assays used to confirm the identity and authenticity of a biologic product (such as monoclonal antibodies, vaccines, cell or gene therapies, and recombinant proteins). The goal is to verify that the tested biologic is the correct product, with the expected molecular structure, sequence, and biological activity, and to distinguish it from other products, impurities, or contaminants.
Identity testing is a regulatory requirement for product release (FDA 21 CFR 610.14, ICH Q6B). Methods vary by product type: peptide mapping and mass spectrometry for protein therapeutics, sequencing and PCR for gene therapies, serological and molecular assays for vaccines. Cell-based potency assays often incorporate identity confirmation.
Industry Segmentation: Service Types & Applications
The Biologics Identity Testing market is segmented by service offering and end-user category:
Method Development and Validation: Custom development and regulatory validation of identity testing methods tailored to specific biologic products. This segment is critical for novel modalities (cell therapies, gene therapies) lacking standard methods. A gene therapy developer recently engaged a CRO to develop and validate identity testing methods for its AAV-based product, meeting FDA IND requirements.
Commercial Support Services: Routine identity testing for commercial biologic products, including release testing and stability monitoring.
Others: Technology transfer, method qualification, and consulting services.
Application Segments
Innovative Biologics Development: Novel biologic developers require identity testing for IND filings, clinical trial supply, and commercialization.
Biosimilars Development: Biosimilar developers require extensive identity comparability studies to demonstrate similarity to reference products. A leading biosimilar manufacturer recently completed identity testing for a monoclonal antibody biosimilar, confirming structural and functional equivalence to the innovator product.
Academic and Research Institutions: Research laboratories require identity confirmation for research-grade biologics and cell therapy products.
Others: Contract manufacturing organizations (CMOs) and blood/tissue establishments.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Next-generation sequencing (NGS) has become standard for identity testing of cell and gene therapies, providing comprehensive genomic characterization. High-resolution mass spectrometry enables detailed protein identity confirmation with minimal sample consumption. Digital PCR (dPCR) offers improved accuracy for viral vector identity testing.
The trend toward integrated analytical platforms combining identity, purity, and potency testing reduces testing timelines. Regulatory expectations for identity testing of cell therapies have increased, requiring donor-to-donor variability assessment. Outsourcing of identity testing to specialized CROs continues as smaller biotechs lack in-house capabilities.
Regional Market Dynamics
North America leads the biologics identity testing market, driven by the largest concentration of biopharmaceutical companies, robust FDA regulatory framework, and strong CRO infrastructure. The United States dominates with significant biologics R&D and commercial manufacturing.
Europe follows closely, with strong biopharma presence in Switzerland, Germany, and the UK, and EMA regulatory requirements driving testing demand. Asia-Pacific is the fastest-growing region, with expanding biologics manufacturing, increasing biosimilar development, and growing CRO capabilities in China, India, South Korea, and Singapore.
Competitive Landscape
Key players include Clean Cells, Charles River Laboratories, SGS SA, Eurofins Scientific, BioAgilytix Labs, Genscript Biotech Corp., AbbVie Inc., Rentschler Biopharma SE, Syngene International Ltd., Thermo Fisher Scientific Inc., GL Biochem Corp., and Abzena plc.
Market Segmentation
The Biologics Identity Testing market is segmented as below:
By Company
Clean Cells
Charles River Laboratories
SGS SA
Eurofins Scientific
BioAgilytix Labs
Genscript Biotech Corp.
AbbVie Inc.
Rentschler Biopharma SE
Syngene International Ltd.
Thermo Fisher Scientific Inc.
GL Biochem Corp.
Abzena plc
Segment by Type
Method Development and Validation
Commercial Support Services
Others
Segment by Application
Innovative Biologics Development
Biologics Development
Academic and Research Institutions
Others
Exclusive Industry Outlook
Looking ahead, the convergence of biologics identity testing with advanced analytics, cell and gene therapy expansion, and regulatory modernization represents a significant growth frontier. Real-time identity testing using process analytical technology (PAT) will enable continuous manufacturing. Development of orthogonal methods for complex cell therapies will address current analytical challenges. Additionally, the trend toward personalized medicines and autologous cell therapies will require rapid, patient-specific identity testing. The ability to offer biologics identity testing that combines regulatory expertise, analytical rigor, and rapid turnaround—supported by global laboratory networks—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For biopharmaceutical quality assurance directors, regulatory affairs professionals, and contract testing organizations, confirming the identity and authenticity of biologic products—monoclonal antibodies, vaccines, cell/gene therapies, and recombinant proteins—is a critical regulatory requirement before product release. The global Biologics Identity Testing market addresses this need through analytical methods and assays that verify product identity, expected molecular structure, sequence, biological activity, and distinguish from impurities or contaminants. As the biologics pipeline expands and regulatory scrutiny intensifies, demand for specialized identity testing services continues to grow.
The global market for Biologics Identity Testing was estimated to be worth US$ 7391 million in 2025 and is projected to reach US$ 12750 million, growing at a CAGR of 8.2% from 2026 to 2032. This steady growth reflects increasing biologic drug approvals, biosimilar development, and outsourcing of testing to specialized CROs.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096823/biologics-identity-testing
Analytical Confirmation for Biologic Product Authenticity
Biologics Identity Testing refers to the set of analytical methods and assays used to confirm the identity and authenticity of a biologic product (such as monoclonal antibodies, vaccines, cell or gene therapies, and recombinant proteins). The goal is to verify that the tested biologic is the correct product, with the expected molecular structure, sequence, and biological activity, and to distinguish it from other products, impurities, or contaminants.
Identity testing is a regulatory requirement for product release (FDA 21 CFR 610.14, ICH Q6B). Methods vary by product type: peptide mapping and mass spectrometry for protein therapeutics, sequencing and PCR for gene therapies, serological and molecular assays for vaccines. Cell-based potency assays often incorporate identity confirmation.
Industry Segmentation: Service Types & Applications
The Biologics Identity Testing market is segmented by service offering and end-user category:
Method Development and Validation: Custom development and regulatory validation of identity testing methods tailored to specific biologic products. This segment is critical for novel modalities (cell therapies, gene therapies) lacking standard methods. A gene therapy developer recently engaged a CRO to develop and validate identity testing methods for its AAV-based product, meeting FDA IND requirements.
Commercial Support Services: Routine identity testing for commercial biologic products, including release testing and stability monitoring.
Others: Technology transfer, method qualification, and consulting services.
Application Segments
Innovative Biologics Development: Novel biologic developers require identity testing for IND filings, clinical trial supply, and commercialization.
Biosimilars Development: Biosimilar developers require extensive identity comparability studies to demonstrate similarity to reference products. A leading biosimilar manufacturer recently completed identity testing for a monoclonal antibody biosimilar, confirming structural and functional equivalence to the innovator product.
Academic and Research Institutions: Research laboratories require identity confirmation for research-grade biologics and cell therapy products.
Others: Contract manufacturing organizations (CMOs) and blood/tissue establishments.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Next-generation sequencing (NGS) has become standard for identity testing of cell and gene therapies, providing comprehensive genomic characterization. High-resolution mass spectrometry enables detailed protein identity confirmation with minimal sample consumption. Digital PCR (dPCR) offers improved accuracy for viral vector identity testing.
The trend toward integrated analytical platforms combining identity, purity, and potency testing reduces testing timelines. Regulatory expectations for identity testing of cell therapies have increased, requiring donor-to-donor variability assessment. Outsourcing of identity testing to specialized CROs continues as smaller biotechs lack in-house capabilities.
Regional Market Dynamics
North America leads the biologics identity testing market, driven by the largest concentration of biopharmaceutical companies, robust FDA regulatory framework, and strong CRO infrastructure. The United States dominates with significant biologics R&D and commercial manufacturing.
Europe follows closely, with strong biopharma presence in Switzerland, Germany, and the UK, and EMA regulatory requirements driving testing demand. Asia-Pacific is the fastest-growing region, with expanding biologics manufacturing, increasing biosimilar development, and growing CRO capabilities in China, India, South Korea, and Singapore.
Competitive Landscape
Key players include Clean Cells, Charles River Laboratories, SGS SA, Eurofins Scientific, BioAgilytix Labs, Genscript Biotech Corp., AbbVie Inc., Rentschler Biopharma SE, Syngene International Ltd., Thermo Fisher Scientific Inc., GL Biochem Corp., and Abzena plc.
Market Segmentation
The Biologics Identity Testing market is segmented as below:
By Company
Clean Cells
Charles River Laboratories
SGS SA
Eurofins Scientific
BioAgilytix Labs
Genscript Biotech Corp.
AbbVie Inc.
Rentschler Biopharma SE
Syngene International Ltd.
Thermo Fisher Scientific Inc.
GL Biochem Corp.
Abzena plc
Segment by Type
Method Development and Validation
Commercial Support Services
Others
Segment by Application
Innovative Biologics Development
Biologics Development
Academic and Research Institutions
Others
Exclusive Industry Outlook
Looking ahead, the convergence of biologics identity testing with advanced analytics, cell and gene therapy expansion, and regulatory modernization represents a significant growth frontier. Real-time identity testing using process analytical technology (PAT) will enable continuous manufacturing. Development of orthogonal methods for complex cell therapies will address current analytical challenges. Additionally, the trend toward personalized medicines and autologous cell therapies will require rapid, patient-specific identity testing. The ability to offer biologics identity testing that combines regulatory expertise, analytical rigor, and rapid turnaround—supported by global laboratory networks—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ